Compare Charles River Laboratories Intl. Inc (CRL) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Wells Fargo & Co — how do they compare? Charles River Laboratories Intl. Inc trades at $228.72 (market cap $11.14B), while Wells Fargo & Co trades at $86.74 (market cap $258.30B). The key difference: Wells Fargo & Co is far larger — about 23.2× Charles River Laboratories Intl. Inc's market cap, and Wells Fargo & Co pays a 2.11% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | WFC | |
|---|---|---|
Market Cap | $11.14B | $258.30B |
Sector | Health | Financials |
52-Week High | $233.60 | $96.40 |
52-Week Low | $145.57 | $73.42 |
Enterprise Value | $14.00B | — |
Dividend Yield | — | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Wells Fargo (WFC) trades at $87.70, up 0.67% with a bullish technical outlook. The stock shows strong fundamentals with Q2 2026 EPS beating estimates at $2.00 versus $1.73 expected, driven by net interest income and fee growth. Revenue trends upward from $83.7B in 2025 to projected $85.0B in 2026, while net income margin remains robust at 25.5%. Recent news highlights the bank's $1B+ technology investment in AI tools for wealth management and a healthy investment banking pipeline.
The outlook is positive with a consensus price target of $99.10 offering 13% upside. Key opportunities include continued earnings momentum and efficiency gains from tech investments. Risks involve expense pressures, macroeconomic sensitivity, and competitive banking sector dynamics. Analyst sentiment is mixed with 45% buy ratings but near-term execution on guidance will be critical for sustained outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
